chrisvoncsefalvay/vaers-outcomes huggingface dataset:
tested positive with COVID; tested positive with COVID; This is a spontaneous report from a contactable consumer (patient) via Pfizer sponsored program. This male patient received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE) via an unspecified route of administration on 01Feb2021 (Lot Number: not reported) at single dose for COVID-19 immunization. The patient's medical history and concomitant medications was not reported. The patient was not able to get the second dose because he tested positive with COVID in Feb2021. The patient wanted to know if it was still okay for him to take the second dose. The outcome of event was unknown.   Information on lot/batch number has been requested.
Fever for 36 hours starting 9 hours after the vaccine - controlled with Tylenol and Advil  Chills, body aches, lethargy, and soreness at the injection site for 36 hours  Nauseous and vomiting for 5 hours starting 12 hours after the vaccine  Headache 36 hours after the vaccine
Patient reported that several hours after getting the vaccine she developed hives.  The hives have spread over the weekend and itch.  Patient denies any shortness of breath.   Patient advised to take Benedryl 25-50mg every 6 hours and Zantac 150 mg twice daily until hives are gone.  Patient advised to go to ER if she has any difficulty breathing.
FLUZONE given 9/9/08. Had lice 9/15/08. Treated with NIX and homeopathic oils. Developed rash seen 9/19 (+) petechiae, bruising, platelet ct = 12. Admit Monday to hospital. Given Win-Rho suspect ITP.  11/26/08 MR received for DOS 9/19-20/2008 with DX: ITP. Pt presented with 1 wk hx of bruising with more recent addition of petechiae and purpura.  Platelet count of 12K at PMD's office.  Admitted for WinRho tx of thrombocytopenia.  Platelet count up to 35K prior to d/c. Will f/u as outpt.
her joint pain increase with covid vaccine; This is a spontaneous report received from contactable reporter (Other HCP).  A 56 year-old female patient received bnt162b2 (Pfizer-BioNTech COVID-19) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation; tofacitinib citrate (XELJANZ XR), since 30Sep2021 (Batch/Lot number: unknown) at 11 mg. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ARTHRALGIA (non-serious), outcome "unknown", described as "her joint pain increase with covid vaccine". The action taken for tofacitinib citrate was unknown.  The lot number for bnt162b2, tofacitinib citrate was not provided and will be requested during follow up.
Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Severe, Additional Details: patient presented to pharmacy with complaint of cellulitis below site of injection with large red patch to upper left arm. she also complained that, with her listing egg as an allergy, she should not have received the shot.
Td 0.1 ml given intradermally into left forearm --no reaction noted, arm rechecked 07/09/2007-no reaction noted , pt notified
Patient returned to pharmacy 23 days after administration complaining of activity limiting muscle pain from shoulder to fingers in left arm. Patient states that pain began as soon as vaccine administered and has remained constant since administration. Patient sought medical treatment after the event and received a medrol dose pack the next day after administration.
p/vax pt lab eval revealed lack of seroconversion: 6/10/98 EIA was 0.28;6/26/98 lab eval was 0 by 2 assays;
17JUN93 fever onset w/moderate rash, fever to 103 w/myoclonic spasm; taken to ER by mom; admitted to hosp 19JUN93; transferred to another hosp 20JUN93; treated w/Rocephin; Depakane, APAP discharged 22JUN93 w/sl rash, fever 99;
Pain at injection site, swelling, headache, muscle aches, joint aches, nausea no vomiting, chills, no rash, fever 103.4 11:30 pm treated with MOTRIN 400 mg temperature decreased 102.7  9/26/06 this am 98.4, dizziness, heart rate 140, pale.
21 days p/ vax pt devel rash, which started on left thigh (inject site) & spread to nape of neck, sternal notch & chest & back. rash was described as grouped vesicles w/redness & central crusting
This spontaneous case was reported by a health care professional and describes the occurrence of SWELLING FACE (Swelling on her face on the left side/swelling continued today, a little bit subsided), CHILLS (Extreme chills/shivering/chattering), FATIGUE (Extremely tired), IRRITABLE BOWEL SYNDROME (irritable bowel syndrome was triggered) and PAIN (Pain) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 051F21A and 006M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. No Medical History information was reported.On 16-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 14-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Nov-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced SWELLING FACE (Swelling on her face on the left side/swelling continued today, a little bit subsided). On an unknown date, the patient experienced CHILLS (Extreme chills/shivering/chattering), FATIGUE (Extremely tired), IRRITABLE BOWEL SYNDROME (irritable bowel syndrome was triggered), PAIN (Pain) and NAUSEA (Extremely nauseous). At the time of the report, SWELLING FACE (Swelling on her face on the left side/swelling continued today, a little bit subsided) was resolving and CHILLS (Extreme chills/shivering/chattering), FATIGUE (Extremely tired), IRRITABLE BOWEL SYNDROME (irritable bowel syndrome was triggered), PAIN (Pain) and NAUSEA (Extremely nauseous) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.No concomitant medications were mentioned. Treatment details stated as Not provided.This case was linked to MOD-2021-388700 (Patient Link).
Pt developed maculopapular rash associated with generalized itchiness without respiratory involvement after receiving anthrax and flumist 18 Nov 08. On 20 Nov 08, pt was also seen in ship's medical with complaint of fever and diff of swallowing, dx with acute tonsilitis and was given azithromycin and tylenol for fever. Pt developed the rash 8 hours after medication were given and 2 days after shot/mist were given.
The patient reported a sharp pain in the center of his chest; Described as a porcupine feeling; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the parent.  A 9 year-old male patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 13Nov2021 11:30 (Lot number: FK5127) at the age of 9 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: INFLUENZA, administration date 25Sep2021. The following information was reported: CHEST PAIN (non-serious) with onset 13Nov2021, outcome "recovered" (2021), described as "The patient reported a sharp pain in the center of his chest"; FEELING ABNORMAL (non-serious) with onset 13Nov2021, outcome "recovered" (2021), described as "Described as a porcupine feeling". The events "the patient reported a sharp pain in the center of his chest" and "described as a porcupine feeling" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Additional information: The patient complained of a sharp pain near the center of his chest maybe 8 hours after getting the 1st dose of the COVID-19 (Comirnaty)-children's dose. The patient described it as having a porcupine in his chest. There were no accompanying clinical signs. They had called doctors office to determine whether they should take him to Urgent Care for evaluation. The patient described his pain level as a 5, maybe 4 1/2. Based on that and absence of other clinical signs, they were told to evaluate/monitor, the patient woke up without any complaints. The next evening the patient mentioned having the same feeling as the previous night after receiving the shot. After that, the patient did not report any additional pain or responses effects. There was no specific relevant test performed for thromboembolic events with thrombocytopenia.  No follow-up attempts are possible. No further information is expected.
About 1 minute after vaccines were administered mother c/o redness and rash to face. Monitored patient for 15 minutes and rash appeared to subside. Instructed mother to follow up with PCP or ER. Mother called back today and stated he had blistered rash on rt leg. Physician did not think is was vaccine related. Instructed mother to call us with any further questions.
Tightness in throat then going into chest, Burning with cough and deep breath, fatigue, body aches. Sought ER treatment per my doctor, ER was back up for over 5 hours, left went home, took benedril. Still having some issues with tightness in chest, burning when taking a breath and cough.
Patient had Fluzone HD, Prevnar 20 and Pfizer bivalent booster on Monday 10/17/2022. Patient called the pharmacy today Thursday 10/20/22 and complains of neck pain. The neck pain is mostly in the back and stiffness up towards base of skull. Neck pain started Tuesday late morning. No fever, no issues at injection site, has full range of motion, can move chin to chest, no other symptoms per patient. Also, stated there was no injection site swelling or redness and barely any pain. Patient is at urgent care now.
Narrative: 57 yo M with history of HCV, Sezary syndrome, hypertension. Received first COVID-19 vaccine on 3/11/21. Reports fatigue, headache, and L arm and leg soreness starting 1 day after vaccine, followed by L>R leg and knee swelling the following day. Presented to ED on 3/17 where exam notes: "LLE moderately edematous from the knee down and slightly tender with palpation. RLE mildly edematous below the knee. Neurovascular status intact, good ROM. Strength 5/5. Patient able to weight-bear and ambulate without difficulty." Duplex negative for DVT; CMP/CBC at baseline. Some improvement (but not resolution) at time of second vaccine appt 4/2. Did receive second vaccine.
Pt c/o waking up at 3:00 AM with pain at the injection site. Pt stated the pain was present when area was touched. Also stated she had an area of redness around injection site about the size of 2 half dollars, and area was warm to the touch. Pt has the ZOSTAVAX vaccine administered.
Hives started 24 hours after vaccine administered, continued until parent called to inform provider on 08/24/11. Hives are relieved with BENADRYL.
I left the store after 15 minutes.  On my drive home I started feeling tingling in my lips, face and scalp.  As I was driving into my driveway (20-25 minutes after the shot) my tongue started feeling strange.  I called my husband and then my doctor.  Doctor told me to take 50 mg of Benadryl.  I felt my heart rate fluctuating, dropping.  I felt like I could pass out.  I had to focus on staying calm and breathing slowly.  After about 30 minutes I started feeling better and by 1 1/2 hours the adverse reaction had passed.
Sitting in chair observer Id'd pt was about to faint.  Was caught and lowered to ground as she lost consciousness.  Almost immediate return to consciousness when on ground, provided juice and water, laid supine.
My son had a febrile seizure in the bath tub and almost drowned. He had already turned blue. Lucky my friend knew CPR and brought him back. I belive it may have been from the flu shot he had recieved. I've written this hoping that you will look into this more and maybe I can help other parents before this happens again.
BOOSTRIX, instead of INFANRIX was administered.  The doses of the Tetanus, Diptheria, Pertussis are less than the INFANRIX.
Rash at injection site; itchiness at the site of reaction; Redness at site of injection; This spontaneous case was reported by a nurse and describes the occurrence of VACCINATION SITE PRURITUS (itchiness at the site of reaction), VACCINATION SITE ERYTHEMA (Redness at site of injection) and VACCINATION SITE RASH (Rash at injection site) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE PRURITUS (itchiness at the site of reaction) and VACCINATION SITE ERYTHEMA (Redness at site of injection). On an unknown date, the patient experienced VACCINATION SITE RASH (Rash at injection site). At the time of the report, VACCINATION SITE PRURITUS (itchiness at the site of reaction), VACCINATION SITE ERYTHEMA (Redness at site of injection) and VACCINATION SITE RASH (Rash at injection site) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  As per the reported follow-up, "the rash she experienced came about 2 weeks after her first vaccine and went away after no more than 3 days as I remember." The reporter considered the patient's reaction as minor and the patient did not seek any medical attention. The patient received the second vaccine dose on an unspecified date and "had no problem."   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2021: Updated outcomes of events to recovered/resolved, dose 2 regimen added, reporter's first name corrected, action taken updated
This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 75-year-old female patient who received SHINGRIX for prophylaxis. On 31st July 2018, the patient received the 1st dose of SHINGRIX (intramuscular). In August 2018, 1 day after receiving SHINGRIX, the patient experienced injection site erythema, injection site itching, injection site tenderness and injection site warmth. The patient was treated with BENADRYL and ibuprofen. On an unknown date, the outcome of the injection site erythema, injection site itching, injection site tenderness and injection site warmth were not recovered/not resolved. It was unknown if the reporter considered the injection site erythema, injection site itching, injection site tenderness and injection site warmth to be related to SHINGRIX. Additional details were reported as follows: This case was previously reported to a physician. The patient received SHINGRIX vaccine in the right arm. The patient experienced the events at the site of her injection about a day or two after receiving the vaccine. The patient continued to have the issues still at the time reporting. The patient notified this to her physician, who told her to contact GlaxoSmithKline (GSK), as he had not given the product and he was not familiar with it. The pharmacist recommended BENADRYL and Ibuprofen. The patient asked, if that was also a recommendation from GSK. The GSK provided medical disclaimer but provided information on side effects and duration from prescribing information. The patient had denied permission to contact their physician.
This boy and his 2 brothers all received Varivax.  Different lot #'s different times.  All have verified Varicella infection now.
This case was reported by a physician and described the occurrence of itching in a 52-year-old female subject who was vaccinated with Fluarix (GlaxoSmithKline) for prophylaxis.  On 28 November 2007 the subject received unspecified dose of Fluarix (.5 ml, unknown, right arm).  On 28 November 2007, less than one day after vaccination with Fluarix, the subject experienced itching and generalized rash on multiple body parts.  The subject was treated with Medrol dose pak and Claritin in the physician's office.  At the time of reporting the events were improved.  The physician considered the events were probably related to vaccination with Fluarix.  Follow-up information received on 11 February 2008 indicated that the events resolved by 13 December 2007 and were considered by the reporter to be related to treatment with Fluarix.  The reporter additionally added that the events jeopardized the subject or required intervention (prescription required).  The events did not appear to be an allergic reaction.  At the age of 39, the subject received tetanus toxoid (manufacturer unknown) and became hot, red and swollen at the injection site (necrotic at the center).  The subject was given antibiotic at that time.  Concurrent medications taken at the time of Fluarix vaccination included Toprol, Mobic, Maxide and Aciphex.  Concurrent medical conditions included hypertension, osteoarthritis, peptic ulcer disease and GERD.
Her blood vessel popped in her left eye; dizzy; very not feeling well; blood pressure went so high/up to 189/100; Interchange of vaccine products; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID. The reporter is the patient.  A 77-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 27Sep2022 as dose 4 (booster), single (Lot number: GH9703) at the age of 77 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. Vaccination history included: moderna vaccine (Moderna LOT: 001J20A , DOSE 1, SINGLE), administration date: 12Jan2021, for Covid-19 immunization, reaction(s): "body ache for 24 hours"; moderna vaccine (LOT: 028L20A, DOSE 2, SINGLE), administration date: 09Feb2021, for Covid-19 immunization, reaction(s): "body ache for 24 hours"; moderna vaccine (LOT: 011F21A, DOSE 3 (BOOSTER), SINGLE), administration date: 09Nov2021, for Covid-19 immunization, reaction(s): "body ache for 24 hours". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 27Sep2022, outcome "unknown"; HYPERTENSION (medically significant) with onset 27Sep2022, outcome "unknown", described as "blood pressure went so high/up to 189/100"; EYE HAEMORRHAGE (medically significant), outcome "unknown", described as "Her blood vessel popped in her left eye"; DIZZINESS (non-serious), outcome "unknown", described as "dizzy"; MALAISE (non-serious), outcome "unknown", described as "very not feeling well". The patient underwent the following laboratory tests and procedures: Blood pressure measurement: (27Sep2022) 189/100, notes: Unit: Not Provided. Therapeutic measures were not taken as a result of eye haemorrhage. Clinical course reported as: After she received the Pfizer COVID-19 vaccine she had very bad side effects and her blood pressure went so high. She was taking medication in regards with her blood pressure. Her blood pressure went so high happened last week, after she got the Pfizer COVID-19 vaccine booster. Last Tuesday when she was in the doctor's office, 27Sep2022, the nurse took her blood pressure and it was normal, then she gave her the shot and she came home and her blood pressure had shot up to 189/100 she believes. Her doctor put her to more medication to bring it down. She was very, very not feeling well, she was very dizzy and her blood pressure has not gotten better even with extra medication. Her blood vessel popped in her left eye when her blood pressure goes up, this happened the day before yesterday. For the popped blood vessel in her left eye she has done no treatment, there was nothing she can do. She asked the doctor and there was nothing she could do, just wait until it went away, it absorbed kind of. She stated that her blood pressure went high and it popped a blood vessel in her left eye.
got really tired and dizzy, starting to slur words, didn't feel like herself, went to ER
Headache, Myalgia, Arthralgia, Fever, NauseaVomiting, achey, joint pain, nauseous, cold, severe HA, body aches Narrative:
Beyond use date of somelot numbers for moderna that were administered to patients; This spontaneous case was reported by a paramedic and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Beyond use date of somelot numbers for moderna that were administered to patients) in a 42-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030h21b) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .25 milliliter. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Beyond use date of somelot numbers for moderna that were administered to patients). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Beyond use date of somelot numbers for moderna that were administered to patients) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient age was reported as 42 years 2 months. Concomitant products were not provided.  It was unknown if patient had acute illness at the time of vaccination and up to one month before. It was unknown if patient had been diagnosed with or tested positive for COVID-19, nor if patient had chronic or long lasting health conditions. It was reported that patient had no adverse reactions after the administration of vaccine.  The vaccination facility was made aware of administration of vaccines beyond use date after the thaw process while audit was conducted. Patient got Moderna with vaccine Ndc code 80777-0273-99.   Treatment medications were not reported.
fever; chills; pain/ Achiness; flu-like symptoms; headache; This case was reported by a pharmacist via call center representative and described the occurrence of fever in an unknown number of adult patients who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced fever, chills, pain, influenza-like symptoms and headache. On an unknown date, the outcome of the fever, chills, pain, influenza-like symptoms and headache were unknown.   It was unknown if the reporter considered the fever, chills, pain, influenza-like symptoms and headache to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The age group was captured as adult as per vaccine indication. The pharmacist reports that many patients had been complaining that they had worse issues after the second dose of Shingrix. She stated that she had been told by patients that after getting the second dose of Shingrix, the patients had experienced fever, chills, pain, headache, achiness, and flu like symptoms. No specific details regarding patient or products was provided at time of reporting. The reporter had consented to follow up.